# MLYS (Mineralys Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Mineralys Therapeutics, Inc. reported $630.1M in total assets and a net loss of $370.0M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/MLYS
- Markdown: https://convexityos.com/fundamentals/MLYS.md
- SEC CIK: 0001933414
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:27 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001933414&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$389.7M | Operating profit |
| Net Income | FY 2025 | -$370.0M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$4.16 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$142.4M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $101.3M | Total debt: $100K |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Research & Development | $132.0M | $168.6M | $70.36M | $26.25M |
| Total Operating Expenses | $170.6M | $192.4M | $84.66M | $31.48M |
| **Operating Income** | -$170.6M | -$192.4M | -$84.66M | -$31.48M |
| **EBITDA** | -$170.5M | -$192.4M | -$84.66M | -- |
| Income Tax Expense | $0 | -- | -- | -- |
| **Net Income** | -$154.7M | -$177.8M | -$71.90M | -$29.80M |
| Basic EPS | -$2.29 | -$3.66 | -$1.99 | -$62.31 |
| **Diluted EPS** | -$2.29 | -$3.66 | -$1.99 | -$62.31 |
| Basic Shares Outstanding | 67.7M | 48.5M | 36.2M | 478.5K |
| Diluted Shares Outstanding | 67.7M | 48.5M | 36.2M | 478.5K |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $22.67M | $221.4M | $24.36M | $24.40M | $31.45M | $38.28M | $37.88M | $44.57M |
| Total Operating Expenses | $60.09M | $246.0M | $45.34M | $38.28M | $41.13M | $46.75M | $44.45M | $51.77M |
| **Operating Income** | -$60.09M | -$246.0M | -$45.34M | -$38.28M | -$41.13M | -$46.75M | -$44.45M | -$51.77M |
| **EBITDA** | -$60.08M | -$246.0M | -$45.33M | -$38.27M | -$41.12M | -$46.73M | -$44.43M | -$51.75M |
| Interest Income | $5.95M | -- | -- | -- | $4.20M | -- | -- | -- |
| Interest Expense | $3.19M | -- | -- | -- | $0 | -- | -- | -- |
| **Net Income** | -$57.33M | -$241.1M | -$39.34M | -$32.23M | -$36.93M | -$43.27M | -$42.21M | -$48.95M |
| Basic EPS | -$0.64 | -$2.85 | -$0.47 | -- | -$0.52 | -$0.66 | -$0.79 | -- |
| **Diluted EPS** | -$0.64 | -$2.85 | -$0.47 | -- | -$0.52 | -$0.66 | -$0.79 | -- |
| Basic Shares Outstanding | 89.0M | 84.7M | 82.8M | -- | 70.6M | 65.5M | 53.2M | -- |
| Diluted Shares Outstanding | 89.0M | 84.7M | 82.8M | -- | 70.6M | 65.5M | 53.2M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $172.9M | $114.1M | $49.30M | $87.70M |
| **Cash & Short-Term Investments** | $172.9M | $114.1M | $49.30M | $87.70M |
| **Total Current Assets** | $661.4M | $205.4M | $249.1M | $112.8M |
| Property, Plant & Equipment, Net | $38K | $53K | $0 | -- |
| Long-Term Investments | -- | $0 | $2.48M | -- |
| Other Non-Current Assets | $382K | $499K | $51K | $1.63M |
| **Total Non-Current Assets** | $420K | $552K | $2.53M | $1.63M |
| **Total Assets** | $661.8M | $205.9M | $251.6M | $114.4M |
| Accounts Payable | $2.02M | $479K | $601K | $1.91M |
| **Total Current Liabilities** | $15.11M | $14.65M | $10.48M | $8.07M |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $158.6M |
| **Total Liabilities** | $15.11M | $14.65M | $10.48M | $166.7M |
| Common Stock | $8.0K | $5.0K | $4.0K | $1.0K |
| Retained Earnings | -$457.2M | -$302.5M | -$124.7M | -$52.81M |
| **Total Stockholders' Equity** | $646.7M | $191.3M | $241.2M | -$52.27M |
| Total Equity | $646.7M | $191.3M | $241.2M | -$52.27M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $101.3M | $138.3M | $112.8M | $172.9M | $217.6M | $101.8M | $165.0M | $114.1M |
| **Cash & Short-Term Investments** | $101.3M | $138.3M | $112.8M | $172.9M | $217.6M | $101.8M | $165.0M | $114.1M |
| **Total Current Assets** | $628.0M | $665.8M | $652.5M | $661.4M | $599.8M | $335.3M | $354.5M | $205.4M |
| Property, Plant & Equipment, Net | $21K | $27K | $32K | $38K | $7.0K | $22K | $38K | $53K |
| Long-Term Investments | -- | -- | -- | -- | -- | -- | -- | $0 |
| Other Non-Current Assets | $2.11M | $2.02M | $360K | $382K | $144K | $433K | $397K | $499K |
| **Total Non-Current Assets** | $2.13M | $2.05M | $392K | $420K | $151K | $455K | $435K | $552K |
| **Total Assets** | $630.1M | $667.9M | $652.9M | $661.8M | $599.9M | $335.7M | $354.9M | $205.9M |
| Accounts Payable | $738K | $1.07M | $1.12M | $2.02M | $1.12M | $3.16M | $373K | $479K |
| **Total Current Liabilities** | $53.08M | $19.32M | $14.72M | $15.11M | $23.52M | $22.17M | $13.39M | $14.65M |
| Long-Term Debt | $100K | $100K | -- | -- | -- | -- | -- | -- |
| **Total Non-Current Liabilities** | $73.27M | $97.62M | $0 | $0 | $0 | $0 | $0 | $0 |
| **Total Liabilities** | $126.3M | $116.9M | $14.72M | $15.11M | $23.52M | $22.17M | $13.39M | $14.65M |
| **Total Debt (incl. Leases)** | $100K | $100K | -- | -- | -- | -- | -- | -- |
| Common Stock | $9.0K | $9.0K | $8.0K | $8.0K | $8.0K | $6.0K | $6.0K | $5.0K |
| Retained Earnings | -$794.9M | -$737.6M | -$496.5M | -$457.2M | -$424.9M | -$388.0M | -$344.7M | -$302.5M |
| **Total Stockholders' Equity** | $503.8M | $550.9M | $638.1M | $646.7M | $576.4M | $313.6M | $341.6M | $191.3M |
| Total Equity | $503.8M | $550.9M | $638.1M | $646.7M | $576.4M | $313.6M | $341.6M | $191.3M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Net Income | -$154.7M | -$177.8M | -$71.90M | -$29.80M |
| Depreciation & Amortization | $59K | $43K | $0 | -- |
| Stock-Based Compensation | $19.32M | $11.34M | $5.06M | $455K |
| **Operating Cash Flow** | -$142.4M | -$166.3M | -$81.17M | -$29.22M |
| Capital Expenditure | -$15K | -$96K | $0 | -- |
| **Free Cash Flow** | -$142.4M | -$166.4M | -$81.17M | -- |
| **Investing Cash Flow** | -$389.8M | $115.0M | -$160.5M | -$21.76M |
| **Financing Cash Flow** | $591.0M | $116.1M | $203.2M | $128.0M |
| **Net Change in Cash** | $58.83M | $64.79M | -$38.40M | $77.04M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$57.33M | -$241.1M | -$39.34M | -$32.23M | -$36.93M | -$43.27M | -$42.21M | -$48.95M |
| Depreciation & Amortization | $6.0K | $5.0K | $6.0K | $13K | $15K | $16K | $15K | $15K |
| Stock-Based Compensation | $7.88M | $7.36M | $6.55M | $5.29M | $5.84M | $4.55M | $3.65M | $3.13M |
| **Operating Cash Flow** | -$43.10M | -$32.56M | -$39.47M | -$37.89M | -$28.87M | -$30.17M | -$45.49M | -$66.84M |
| Capital Expenditure | -- | -- | -- | -$15K | $0 | $0 | $0 | $0 |
| **Free Cash Flow** | -- | -- | -- | -$37.90M | -$28.87M | -$30.17M | -$45.49M | -$66.84M |
| **Investing Cash Flow** | $4.70M | -$185.2M | -$44.94M | -$103.5M | -$150.5M | -$42.88M | -$92.88M | $83.57M |
| Common Stock Issued | -- | -- | -- | -- | -- | -- | $189.2M | -- |
| **Financing Cash Flow** | $1.40M | $243.3M | $24.27M | $96.70M | $295.2M | $9.83M | $189.3M | $90K |
| **Net Change in Cash** | -$36.99M | $25.49M | -$60.14M | -$44.68M | $115.8M | -$63.22M | $50.92M | $16.82M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -23.9% | -93.0% | -29.8% | -- |
| Return on Assets (ROA) | -23.4% | -86.4% | -28.6% | -26.0% |
| Current Ratio | 43.76x | 14.02x | 23.76x | 13.98x |
| Quick Ratio | 11.44x | 7.79x | 4.70x | 10.87x |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -73.4% | -63.5% | -23.8% | -23.9% | -29.7% | -60.8% | -55.2% | -93.0% |
| Return on Assets (ROA) | -58.7% | -52.3% | -23.2% | -23.4% | -28.6% | -56.8% | -53.1% | -86.4% |
| Current Ratio | 11.83x | 34.46x | 44.33x | 43.76x | 25.50x | 15.12x | 26.48x | 14.02x |
| Quick Ratio | 1.91x | 7.16x | 7.66x | 11.44x | 9.25x | 4.59x | 12.33x | 7.79x |
| Debt to Equity | 0.00x | 0.00x | -- | -- | -- | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
